BeOne Medical Affairs· @BeOneMedAffairs · X·· 2 days agoScore70
Body
At #ESMO26, we shared the second interim analysis from HERIZON-GEA-01, evaluating a HER2-directed bispecific antibody with chemotherapy, with or without a PD-1 inhibitor, in first-line HER2-positive advanced/metastatic gastroesophageal adenocarcinoma.
Learn more on BeOne Medical: http://bit.ly/4hHLXMs
70 views · 2 likes · 0 reposts · 0 replies
Conference abstracts
LBA79matched by Rapid oral 1: Gastrointestinal tumour, upper digestive
Zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): Second interim analysis (IA) from HERIZON-GEA-01
https://esmocongress.esmo.orgSource: BeOne Medical Affairs · x.com